Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - Donepezil (Aricept), is a centrally acting reversible acetyl cholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine. Donepezil is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, donepezil's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. Donepezil has been tested in other cognitive disorders including Lewy body dementia and Vascular dementia, but it is not currently approved for these indications. Donepezil has also been studied in patients with Mild Cognitive Impairment, schizophrenia, attention deficit disorder, post-coronary bypass cognitive impairment, cognitive impairment associated with multiple sclerosis, and Down syndrome. (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...generalReferences
| - # Xiong G, Doraiswamy PM: Combination drug therapy for Alzheimer's disease: what is evidence-based, and what is not? Geriatrics. 2005 Jun;60(6):22-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15948662 # Yesavage JA, Mumenthaler MS, Taylor JL, Friedman L, O'Hara R, Sheikh J, Tinklenberg J, Whitehouse PJ: Donepezil and flight simulator performance: effects on retention of complex skills. Neurology. 2002 Jul 9;59(1):123-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12105320 # Sugimoto H: Donepezil hydrochloride: a treatment drug for Alzheimer's disease. Chem Rec. 2001;1(1):63-73. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11893059 (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| |
http://linked.open...ugbank/indication
| - For the palliative treatment of mild to moderate dementia of the Alzheimer's type. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Donepezil is a piperidine derivative that is a centerally active, reversible inhibitor of acetylcholinesterase. This drug is structurally unrelated to other anticholinesterase agents. Donepezil's proposed mechanism of action involves the reversible inhibition of cholinesterases (eg. acetylcholinesterase), which prevents the hydrolysis of acetycholine, and leads to an increased concentration of acetylcholine at cholinergic synapses. Evidence suggests that the anticholinesterase activity of donepezil is relatively specific for acetylcholinesterase in the brain. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...y/drugbank/patent
| |
http://linked.open...outeOfElimination
| - Donepezil is both excreted in the urine intact and extensively metabolized to four major metabolites, two of which are known to be active, and a number of minor metabolites, not all of which have been identified. (en)
|
http://linked.open.../drugbank/synonym
| - Donepezil (en)
- Domepezil (en)
- Donepezilo (en)
- Donepezilum (en)
|
http://linked.open...drugbank/toxicity
| - Symptoms of overdose include severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. (en)
|
http://linked.open...umeOfDistribution
| |
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...k/foodInteraction
| - Avoid alcohol. (en)
- Take without regard to meals. (en)
|
http://linked.open.../drugbank/mixture
| |
http://linked.open...nk/proteinBinding
| |
http://linked.open...ogy/drugbank/salt
| |
http://linked.open...ynthesisReference
| - Akio Imai, Hideaki Watanabe, Takashi Kajima, Yasushi Ishihama, Akiyo Ohtsuka, Tomohide Tanaka, Yukio Narabu, "Polymorphs of donepezil hydrochloride and process for production." U.S. Patent US5985864, issued December, 1988. (en)
|
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Donepezil is well absorbed with a relative oral bioavailability of 100% and reaches peak plasma concentrations in 3 to 4 hours. (en)
|
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...rugbank/clearance
| - * apparent plasma cl=0.13 L/hr/kg (en)
|
http://linked.open...gbank/containedIn
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...ank/Melting-Point
| |